Germline genetic predictors of aromatase inhibitor concentrations, estrogen suppression and drug efficacy and toxicity in breast cancer patients
出版年份 2017 全文链接
标题
Germline genetic predictors of aromatase inhibitor concentrations, estrogen suppression and drug efficacy and toxicity in breast cancer patients
作者
关键词
-
出版物
PHARMACOGENOMICS
Volume 18, Issue 5, Pages 481-499
出版商
Future Medicine Ltd
发表日期
2017-03-28
DOI
10.2217/pgs-2016-0205
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- CYP1A2 – a novel genetic marker for early aromatase inhibitor response in the treatment of breast cancer patients
- (2016) Maria Simonsson et al. BMC CANCER
- Fulvestrant decreases anastrozole drug concentrations when taken concurrently by patients with metastatic breast cancer treated on SWOG study S0226
- (2016) Daniel L. Hertz et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Abstract PD2-01: Randomized phase 3 trial of adjuvant letrozole versus anastrozole in postmenopausal patients with hormone receptor positive, node positive early breast cancer: Final efficacy and safety results of the femara versus anastrozole clinical evaluation (Face) trial
- (2016) J O'Shaughnessy et al. CANCER RESEARCH
- Genetic Polymorphisms in the Long Noncoding RNA MIR2052HG Offer a Pharmacogenomic Basis for the Response of Breast Cancer Patients to Aromatase Inhibitor Therapy
- (2016) James N. Ingle et al. CANCER RESEARCH
- Genetic variant in the osteoprotegerin gene is associated with aromatase inhibitor-related musculoskeletal toxicity in breast cancer patients
- (2016) A. Lintermans et al. EUROPEAN JOURNAL OF CANCER
- Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Early Breast Cancer: TEXT and SOFT Trials
- (2016) Meredith M. Regan et al. JOURNAL OF CLINICAL ONCOLOGY
- Estrogen, SNP-Dependent Chemokine Expression and Selective Estrogen Receptor Modulator Regulation
- (2016) Ming-Fen Ho et al. MOLECULAR ENDOCRINOLOGY
- Patient-Reported Outcomes and Early Discontinuation in Aromatase Inhibitor-Treated Postmenopausal Women With Early Stage Breast Cancer
- (2016) Kunal C. Kadakia et al. ONCOLOGIST
- Impact of nonsynonymous single nucleotide polymorphisms on in-vitro metabolism of exemestane by hepatic cytosolic reductases
- (2016) Amity Platt et al. Pharmacogenetics and Genomics
- Polymorphisms in drug-metabolizing enzymes and steady-state exemestane concentration in postmenopausal patients with breast cancer
- (2016) D L Hertz et al. PHARMACOGENOMICS JOURNAL
- Impact of mutational profiles on response of primary oestrogen receptor-positive breast cancers to oestrogen deprivation
- (2016) Pascal Gellert et al. Nature Communications
- Influence of CYP19A1 polymorphisms on the treatment of breast cancer with aromatase inhibitors: a systematic review and meta-analysis
- (2015) Osvaldo Artigalás et al. BMC Medicine
- ESR1 and ESR2 polymorphisms in the BIG 1-98 trial comparing adjuvant letrozole versus tamoxifen or their sequence for early breast cancer
- (2015) Brian Leyland-Jones et al. BREAST CANCER RESEARCH AND TREATMENT
- CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1–98 trial
- (2015) Brian Leyland-Jones et al. BREAST CANCER RESEARCH AND TREATMENT
- Associations between genetic variants and the effect of letrozole and exemestane on bone mass and bone turnover
- (2015) Steffi Oesterreich et al. BREAST CANCER RESEARCH AND TREATMENT
- Association of Variants in Candidate Genes with Lipid Profiles in Women with Early Breast Cancer on Adjuvant Aromatase Inhibitor Therapy
- (2015) C. A. Santa-Maria et al. CLINICAL CANCER RESEARCH
- CYP19A1fine-mapping and Mendelian randomization: estradiol is causal for endometrial cancer
- (2015) Deborah J Thompson et al. ENDOCRINE-RELATED CANCER
- Treatment-Associated Musculoskeletal and Vasomotor Symptoms and Relapse-Free Survival in the NCIC CTG MA.27 Adjuvant Breast Cancer Aromatase Inhibitor Trial
- (2015) Vered Stearns et al. JOURNAL OF CLINICAL ONCOLOGY
- Impact ofUGT2B17Gene Deletion on the Pharmacokinetics of 17-Hydroexemestane in Healthy Volunteers
- (2015) Shanly M. Chen et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials
- (2015) LANCET
- Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer
- (2015) Nicholas C. Turner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Genetic polymorphism at Val80 (rs700518) of the CYP19A1 gene is associated with body composition changes in women on aromatase inhibitors for ER (+) breast cancer
- (2015) Nicola Napoli et al. Pharmacogenetics and Genomics
- RANKL and OPG Polymorphisms Are Associated with Aromatase Inhibitor-Related Musculoskeletal Adverse Events in Chinese Han Breast Cancer Patients
- (2015) Jingxuan Wang et al. PLoS One
- Estrogens and their precursors in postmenopausal women with early breast cancer receiving anastrozole
- (2015) James N. Ingle et al. STEROIDS
- Association Between ESR1 PvuII, XbaI, and P325P Polymorphisms and Breast Cancer Susceptibility: A Meta-Analysis
- (2015) Yiming Zhang et al. MEDICAL SCIENCE MONITOR
- A prospective assessment of musculoskeletal toxicity and loss of grip strength in breast cancer patients receiving adjuvant aromatase inhibitors and tamoxifen, and relation with BMI
- (2014) A. Lintermans et al. BREAST CANCER RESEARCH AND TREATMENT
- Germline variants in the CYP19A1 gene are related to specific adverse events in aromatase inhibitor users: a substudy of Dutch patients in the TEAM trial
- (2014) Duveken B. Y. Fontein et al. BREAST CANCER RESEARCH AND TREATMENT
- Arthralgia induced by endocrine treatment for breast cancer: A prospective study of serum levels of insulin like growth factor-I, its binding protein and oestrogens
- (2014) Anneleen Lintermans et al. EUROPEAN JOURNAL OF CANCER
- Effect of Estrogen Depletion on Pain Sensitivity in Aromatase Inhibitor–Treated Women With Early-Stage Breast Cancer
- (2014) N. Lynn Henry et al. JOURNAL OF PAIN
- Aromatase Inhibitor-Associated Bone Fractures: A Case-Cohort GWAS and Functional Genomics
- (2014) Mohan Liu et al. MOLECULAR ENDOCRINOLOGY
- Genetic polymorphism at Val80 (rs700518) of the CYP19A1 gene is associated with aromatase inhibitor associated bone loss in women with ER (+) breast cancer
- (2013) Nicola Napoli et al. BONE
- Genetic determinants of aromatase inhibitor-related arthralgia: the B-ABLE cohort study
- (2013) Natalia Garcia-Giralt et al. BREAST CANCER RESEARCH AND TREATMENT
- Genetic associations with toxicity-related discontinuation of aromatase inhibitor therapy for breast cancer
- (2013) N. Lynn Henry et al. BREAST CANCER RESEARCH AND TREATMENT
- A Polymorphism at the 3'-UTR Region of the Aromatase Gene Is Associated with the Efficacy of the Aromatase Inhibitor, Anastrozole, in Metastatic Breast Carcinoma
- (2013) Lei Liu et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Specific Adverse Events Predict Survival Benefit in Patients Treated With Tamoxifen or Aromatase Inhibitors: An International Tamoxifen Exemestane Adjuvant Multinational Trial Analysis
- (2013) Duveken B.Y. Fontein et al. JOURNAL OF CLINICAL ONCOLOGY
- Genome-wide association study of sex hormones, gonadotropins and sex hormone–binding protein in Chinese men
- (2013) Zhuo Chen et al. JOURNAL OF MEDICAL GENETICS
- Genome-wide association studies on serum sex steroid levels
- (2013) Liesbeth Vandenput et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- Activating ESR1 mutations in hormone-resistant metastatic breast cancer
- (2013) Dan R Robinson et al. NATURE GENETICS
- Indications of Clinical and Genetic Predictors for Aromatase Inhibitors Related Musculoskeletal Adverse Events in Chinese Han Women with Breast Cancer
- (2013) Jingxuan Wang et al. PLoS One
- Plasma estrone sulfate concentrations and genetic variation at the CYP19A1 locus in postmenopausal women with early breast cancer treated with letrozole
- (2012) G. Lunardi et al. BREAST CANCER RESEARCH AND TREATMENT
- Polymorphisms of CYP19A1 and response to aromatase inhibitors in metastatic breast cancer patients
- (2012) Roberta Ferraldeschi et al. BREAST CANCER RESEARCH AND TREATMENT
- The pharmacokinetics of letrozole its association with key body mass metrics
- (2012) Seok-Joon Jin et al. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
- Suppression of Plasma Estrogen Levels by Letrozole and Anastrozole Is Related to Body Mass Index in Patients With Breast Cancer
- (2012) Elizabeth J. Folkerd et al. JOURNAL OF CLINICAL ONCOLOGY
- Predictors of Aromatase Inhibitor Discontinuation as a Result of Treatment-Emergent Symptoms in Early-Stage Breast Cancer
- (2012) N. Lynn Henry et al. JOURNAL OF CLINICAL ONCOLOGY
- Genome-Wide Association Study of Circulating Estradiol, Testosterone, and Sex Hormone-Binding Globulin in Postmenopausal Women
- (2012) Jennifer Prescott et al. PLoS One
- The time since last menstrual period is important as a clinical predictor for non-steroidal aromatase inhibitor-related arthralgia
- (2011) Miyuki Kanematsu et al. BMC CANCER
- Single nucleotide polymorphisms of CYP19A1 predict clinical outcomes and adverse events associated with letrozole in patients with metastatic breast cancer
- (2011) In Hae Park et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Plasma Letrozole Concentrations in Postmenopausal Women With Breast Cancer Are Associated With CYP2A6 Genetic Variants, Body Mass Index, and Age
- (2011) Z Desta et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Population pharmacokinetic analysis of letrozole in Japanese postmenopausal women
- (2011) Hiromi Tanii et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Pharmacology of arthralgia with estrogen deprivation
- (2011) Anneleen Lintermans et al. STEROIDS
- A polymorphism at the 3'-UTR region of the aromatase gene defines a subgroup of postmenopausal breast cancer patients with poor response to neoadjuvant letrozole
- (2010) Zaida Garcia-Casado et al. BMC CANCER
- In vitro and in vivo oxidative metabolism and glucuronidation of anastrozole
- (2010) Landry K. Kamdem et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Functional Genetic Polymorphisms in the Aromatase Gene CYP19 Vary the Response of Breast Cancer Patients to Neoadjuvant Therapy with Aromatase Inhibitors
- (2010) L. Wang et al. CANCER RESEARCH
- Variation in Anastrozole Metabolism and Pharmacodynamics in Women with Early Breast Cancer
- (2010) J. N. Ingle et al. CANCER RESEARCH
- In Vitro Cytochrome P450-Mediated Metabolism of Exemestane
- (2010) L. K. Kamdem et al. DRUG METABOLISM AND DISPOSITION
- Genome-Wide Associations and Functional Genomic Studies of Musculoskeletal Adverse Events in Women Receiving Aromatase Inhibitors
- (2010) James N. Ingle et al. JOURNAL OF CLINICAL ONCOLOGY
- Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia
- (2010) Akinbode Egbelakin et al. PEDIATRIC BLOOD & CANCER
- Characterization of 17-dihydroexemestane glucuronidation: potential role of the UGT2B17 deletion in exemestane pharmacogenetics
- (2010) Dongxiao Sun et al. Pharmacogenetics and Genomics
- Effect of a switch of aromatase inhibitors on musculoskeletal symptoms in postmenopausal women with hormone-receptor-positive breast cancer: the ATOLL (articular tolerance of letrozole) study
- (2009) Karine Briot et al. BREAST CANCER RESEARCH AND TREATMENT
- Patterns and risk factors associated with aromatase inhibitor-related arthralgia among breast cancer survivors
- (2009) Jun J. Mao et al. CANCER
- Deactivation of anti-cancer drug letrozole to a carbinol metabolite by polymorphic cytochrome P450 2A6 in human liver microsomes
- (2009) K. Murai et al. XENOBIOTICA
- Letrozole is Superior to Anastrozole in Suppressing Breast Cancer Tissue and Plasma Estrogen Levels
- (2008) J. Geisler et al. CLINICAL CANCER RESEARCH
- A Single-Nucleotide Polymorphism in the Aromatase Gene Is Associated with the Efficacy of the Aromatase Inhibitor Letrozole in Advanced Breast Carcinoma
- (2008) R. Colomer et al. CLINICAL CANCER RESEARCH
- Letrozole Suppresses Plasma Estradiol and Estrone Sulphate More Completely Than Anastrozole in Postmenopausal Women With Breast Cancer
- (2008) J. Michael Dixon et al. JOURNAL OF CLINICAL ONCOLOGY
- Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial
- (2008) Jack Cuzick et al. LANCET ONCOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started